| Gene symbol | CLU | Synonyms | AAG4, APO-J, APOJ, CLI, CLU1, CLU2, KUB1, NA1/NA2, SGP-2, SGP2, SP-40, TRPM-2, TRPM2 | Type of gene | protein-coding |
| Chromosome | 8 | Map location | 8p21.1 | dbXrefs | |
| Description | clusterin | ||||
| GTO ID | GTC1271 |
| Trial ID | NCT00471432 |
| Disease | Breast Cancer | Ovarian Cancer | Bladder Cancer | Lung Cancer | Prostate Cancer | Kidney Cancer |
| Altered gene | CLU |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | OGX-011|custirsen sodium|TV-1011 |
| Co-treatment | docetaxel |
| Phase | Phase1 |
| Recruitment status | Completed |
| Title | A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel |
| Year | 2007 |
| Country | Canada |
| Company sponsor | NCIC Clinical Trials Group |
| Other ID(s) | I154|CAN-NCIC-IND154|ONCOGENEX-OGX-01-02|CDR0000547039 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||